Gynea Laboratorios

What Gynea Laboratorios does

Gynea Laboratorios is the dedicated women's health division of the Spanish pharmaceutical company Kern Pharma, headquartered in Barcelona. Founded in 1999 and operating with 101-250 employees, it develops and markets a portfolio of over 22 pharmaceutical and nutritional products exclusively formulated for women across all major life stages — intimate care, preconception and pregnancy, fertility, breastfeeding, contraception, menopause, deficiency states, polycystic ovary syndrome (PCOS), and sexual health. The portfolio comprises both prescription medications regulated as EFG generics by AEMPS — including the combined oral contraceptive Danielle (dienogest/ethinyl estradiol) and the contraceptive vaginal ring Ringo (etonogestrel/ethinyl estradiol) — and a broad over-the-counter supplement and intimate care franchise under sub-brands such as Melagyn, Gestagyn, GyneFer, Aquistik, Dismegyn, CimiNocta, GynFeel, and Longyvit.

The business operates a B2B2C and pharmacy-channel model: products are distributed through Kern Pharma's established pharmacy network in Spain and Portugal, with official regulated Spanish retail pricing (PVL / PVP / PVP IVA) on prescription lines. Public-facing product pages require healthcare-professional verification, indicating a B2B / healthcare-professional-led go-to-market motion layered on top of consumer demand. Consumer engagement is built through the 'Mujer sin filtros' educational blog, a suite of interactive life-stage calculators (fertility days, due date, pregnancy weight, baby percentile, calcium, menopause symptom tracking), and active Instagram and Facebook channels.

Gynea generates revenue through one-time unit sales of prescription pharmaceuticals and recurring use of OTC supplements and intimate care products, sold via mass-market pharmacy retail at consumer price points ranging from approximately €9.90 (single Ringo unit) to €39.99 (3-month Danielle pack). As a division rather than a standalone legal entity, Gynea has no external shareholders, no independent funding history, and no separately reported financials; its capacity for product expansion, geographic extension, and marketing is determined by Kern Pharma's parent-level strategic and capital allocation decisions.

Name

Gynea Laboratorios

Legal name

Gynea Laboratorios

Website

https://gynea.com

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

101–250 employees

Short description

Gynea Laboratorios is the women's health division of Spanish pharmaceutical company Kern Pharma, headquartered in Barcelona. It markets 22-plus prescription pharmaceuticals and OTC supplements — across contraception, pregnancy, fertility, menopause, intimate care, and PCOS — through pharmacy channels in Spain and Portugal.

Ownership category

akta.pro rank

Product category

Women's Health Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Women’s Health & Reproductive Specialty Pharmaceuticals (HLAIACAN)

akta.pro secondary industries

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Family Planning & Contraception (Including Abortion Care) (HLAKAJAG), Women’s Health Supplements (Prenatal, Menopause, Hormonal) (CRADAGAK), Menstrual Pain Relief & Period Care Supplements (CRABAIAJ)

Keywords

• Women's health pharmaceuticals
• Hormonal contraceptives
• Intimate hygiene products
• Pregnancy supplements
• Menopause nutritional supplements

Headquarters

HQ city

Barcelona

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations, Others

Revenue model

1. Prescription Pharmaceuticals: Gynea generates revenue through prescription pharmaceutical products sold via pharmacy channels. Products include oral contraceptives (Danielle), vaginal rings (Ringo), and topical intimate care products that require medical prescription or are available over-the-counter.
2. Dietary Supplements: Revenue from nutritional supplements including Gestagyn product line (preconception, pregnancy, lactation), CimiNocta (menopause), Aquistik (PCOS), and Longyvit (women 40+), sold through pharmacy distribution.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Gynea Laboratorios develops, manufactures, and distributes a portfolio of prescription pharmaceuticals and food supplements exclusively formulated for women's health across all life stages. Core offerings include prescription hormonal contraceptives (Danielle oral tablets and Ringo vaginal ring), intimate hygiene products (Melagyn line), pregnancy and fertility supplements (Gestagyn line, GyneFer), menopause support (CimiNocta, Longyvit), and PCOS-specific nutritional supplements (Aquistik, Dismegyn). Products are distributed through pharmacy channels in Spain and Portugal.

Product overview

Gynea Laboratorios is the women's health division of Kern Pharma, offering a comprehensive portfolio of pharmaceutical products and food supplements exclusively formulated for women across all stages of life. The product portfolio spans seven therapeutic areas: intimate protection (Melagyn® line including gel, mousse, pediatric, simbiótico, pregnancy, wipes, spray, vulvar and vaginal moisturizers, vaginal solution, and vaginal suppositories), pregnancy (Gestagyn® Embarazo, Melagyn® Embarazo), fertility (Gestagyn® Preconcepción, Gestagyn® Men), breastfeeding (Gestagyn® Lactancia), menopause (CimiNocta®, CimiNocta® Forte, Longyvit®), contraceptives (Ringo® vaginal ring, Danielle® oral contraceptive), deficiency states (GyneFer® iron supplement, Longyvit®), polycystic ovary syndrome (Aquistik®, Dismegyn®), and sexual health (GynFeel®). The portfolio includes both prescription medications (EFG/generics) regulated by AEMPS and over-the-counter food supplements.

Differentiator

Problem solved

Functional benefit

Brands

• Melagyn®: Product line for intimate hygiene including gel, mousse, pediatric, spray, intimate wipes, vaginal solution, and ovules
• Gestagyn®
• GyneFer®
• Aquistik®
• Dismegyn®
• CimiNocta®
• GynFeel®
• Longyvit®
• Ringo®
• Danielle®

Products and services

• Melagyn Gel Intimate hygiene gel formulated for respectful and effective intimate care, distributed through pharmacies in Spain and Portugal.
• Melagyn Mousse Intimate hygiene mousse formulated for sensitive skin with neutral pH.
• Melagyn Pediatric Intimate hygiene product specifically formulated for children.
• Melagyn Simbiótico Symbiotic food supplement containing probiotics, prebiotics, and vitamins A, C, and E for intimate health.
• Melagyn Embarazo Daily intimate hygiene gel specifically formulated for pregnant women, postpartum, and breastfeeding mothers.
• Melagyn Toallitas Intimate hygiene and protection wipes for use anytime, anywhere.
• Melagyn Spray Topical solution designed to refresh the intimate area and restore comfort immediately.
• Melagyn Hidratante Vulvar External intimate hydrating gel formulated to improve vulvar comfort immediately.
• Melagyn Hidratante Vaginal Mucoadhesive intimate hydrating gel for the relief of vaginal dryness.
• Melagyn Solución Vaginal Local treatment for infections and inflammations of the vulva and vagina.
• Melagyn Óvulos Vaginales Vaginal suppositories to help restore natural balance and well-being in the intimate area.
• Gestagyn Preconcepción Food supplement formulated to prepare for pregnancy and support preconception nutritional needs.
• Gestagyn Men Food supplement formulated specifically for male fertility.
• Gestagyn Embarazo Food supplement formulated to complement nutritional needs during pregnancy.
• Gestagyn Lactancia Food supplement formulated to cover the nutritional needs of mother and baby during breastfeeding.
• GyneFer Next-generation iron supplement for women addressing iron deficiency states.
• Aquistik Food supplement formulated to improve hormonal and metabolic imbalance associated with Polycystic Ovary Syndrome (PCOS).
• Dismegyn Medication containing dry extract of Vitex agnus-castus L. (Chasteberry) indicated for the relief of breast swelling and painful tension associated with premenstrual syndrome.
• CimiNocta Natural supplement formulated to help control menopausal hot flashes.
• CimiNocta Forte Food supplement formulated to combat menopause symptoms with intensified formulation.
• GynFeel Food supplement formulated to support women's sexual health.
• Longyvit Food supplement with DHA from microalgae, 13 vitamins and 7 minerals, designed for the nutritional needs of women over 40.
• Ringo Prescription combined low-dose hormonal contraceptive vaginal ring releasing 0.120 mg etonogestrel and 0.015 mg ethinyl estradiol per 24 hours over 3 weeks.
• Danielle Prescription combined low-dose oral contraceptive containing 2 mg dienogest and 0.03 mg ethinyl estradiol, also indicated for improvement of androgenic acne symptoms.

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Kern PharmaOthersGynea is the Women's Health division of Kern Pharma, a Spanish pharmaceutical company headquartered in Barcelona. Products are developed under Kern Pharma's quality standards and distributed through their pharmaceutical infrastructure.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• HRA Pharma (Perrigo): Specialty pharma focused on women's health, endocrinology and rare diseases, now part of Perrigo. Comparable portfolio in emergency contraception, menopause and reproductive health with European roots.
• Bayer: Global pharmaceutical incumbent whose Pharma division includes a major women's health franchise (Yaz/Yasmin, Mirena, Kyleena). Comparable categories but operates as part of a much larger, diversified portfolio.
• Gedeon Richter: Hungary-headquartered multinational pharmaceutical company with a meaningful women's health franchise (contraceptives, fertility, menopause). Broader portfolio but directly competes in Gynea's core categories.

Direct peers

• Organon: Global women's health pure-play spun off from Merck, with a portfolio spanning contraception, fertility, menopause and biosimilars. Directly comparable as a women's-health-focused pharma with branded Rx and established physician relationships.
• Effik: European specialty pharmaceutical company focused on women's health (contraception, menopause, intimate care) with pharmacy-led distribution in France, Italy, Spain and Portugal. Directly comparable portfolio and channel model.
• Theramex: Specialty pharmaceutical company dedicated to women's health across contraception, fertility, menopause and osteoporosis, operating across multiple European markets with a similar Rx plus supplement mix and pharmacy-channel distribution.
• Exeltis: Pharmaceutical company within the Insud Pharma group focused on women's health, with strong presence in Spain, Portugal and Latin America across contraception, fertility, pregnancy and menopause. Closely comparable in geography, channel and product mix.

Emerging players

• Veru Inc. US-listed specialty pharma focused on women's health (contraception, menopause, oncology supportive care). Overlaps with Gynea's therapeutic focus and channel but operates at much smaller scale and primarily in the US.

Regional players

• Laboratorios Casen Recordati: Spanish specialty pharmaceutical company within the Recordati group, focused on women's intimate health and gastroenterology. Closely comparable Iberian presence and pharmacy-channel focus.
• Italfarmaco: Italian specialty pharmaceutical group with a women's health portfolio spanning gynaecology, menopause and fertility. Comparable product mix but primarily operates in Italy and selected European markets rather than Iberia.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/gyneamujersinfiltros
• Instagraminstagram.com/gyneamujersinfiltros
• Xx.com/labgynea

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gynea Laboratorios